Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)
Pierre Morel, Christian Buske, Alexander Grunenberg, Efstathios Kastritis, Lydia Montes, Cécile Tomowiak, Roman Hájek, Andreas Viardot, Olivier Tournilhac, Thérèse Aurran, Florian Bouclet, Hacène Zerazhi, Bénédicte Hivert, Damien Roos‐Weil, Sophie de Guibert, Lena Brandefors, Ramón García‐Sánz, Maria Fátima das Graças Fernandes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Mélanie Verlay, Caroline Skrzypczak, Jens Dreyhaupt, Rainer Muche, Meletios A Dimopoulos (2025). Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-223.
